Pfizer CEO Announces Several New Partnerships with Gene Editing Companies, Including Beam Therapeutics, Codex DNA and Acuitas

“Producing an mRNA-based Covid vaccine gave Pfizer expertise to apply to other mRNA opportunities, such as base editing, Beam Chief Executive Officer John Evans said Monday in an interview with Bloomberg Television. Pfizer and Beam plan to use mRNA to deliver edits that, if successful, would change a person’s DNA to fix or possibly even cure genetic disease.”

https://www.bloomberg.com/news/articles/2022-01-10/pfizer-deepens-commitment-to-genetic-drug-future-with-deals

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

%d bloggers like this: